StreetInsider.com News Articles

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

Prolynx, a biotechnology company developing ultra-long-acting medicines for obesity and metabolic diseases, has appointed Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer, according to a company statement.

Harnest brings experience in life sciences finance, including involvement in three Nasdaq IPOs and more than $1 billion in capital raised. He most recently served as CFO of Totus Medicines and previously held senior roles at Metagenomi (Nasdaq: MGX) and Cellectis (Nasdaq: CLLS).

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

Wed, 15 Jul 2026 08:00:00 -0400

EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer. The appointments deepen the company’s leadership bench as Prolynx advances multiple ultra-long-acting candidates for obesity and related metabolic diseases toward IND-enabling studies.